BESINS Healthcare has confirmed that global supply has been interrupted and that Testogel (1% transdermal testosterone gel) sachets would be unavailable in Australia for several months.
To avoid treatment disruption, patients treated with Testogel sachets are advised they will need to secure a new prescription for the Testogel pump presentation, which is unaffected by supply issues.
The company reassured healthcare professionals and consumers that Testogel sachets and Testogel pump provide the same strength and dose range, but require separate scripts.
Besins md Geoff Blundell apologised to patients, doctors and pharmacists for any inconvenience arising from the supply issue, especially as it follows the unexpected withdrawal of competitor product, Lily's Axiron (2% w/v transdermal testosterone solution) at the end of last year (PD 15 Nov 17), which has created increased demand for Testogel.
The company stressed that the product was not being discontinued and that GPs could prescribe the pump presentation without the patient having to revisit a specialist.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Mar 18
